These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

51 related items for PubMed ID: 19743939

  • 1. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships.
    Hollak CE, de Fost M, van Dussen L, Vom Dahl S, Aerts JM.
    Expert Opin Pharmacother; 2009 Nov; 10(16):2641-52. PubMed ID: 19743939
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 3. Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy.
    Beutler E.
    Blood Cells Mol Dis; 2000 Aug; 26(4):303-6. PubMed ID: 11042031
    [No Abstract] [Full Text] [Related]

  • 4. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):119-23. PubMed ID: 20727796
    [Abstract] [Full Text] [Related]

  • 5. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug 15; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

  • 6. A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease.
    Zimran A, Loveday K, Fratazzi C, Elstein D.
    Blood Cells Mol Dis; 2007 Aug 15; 39(1):115-8. PubMed ID: 17391996
    [Abstract] [Full Text] [Related]

  • 7. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J, Dulisse B, Grabowski GA, Weinreb NJ.
    Clin Genet; 2007 Mar 15; 71(3):205-11. PubMed ID: 17309642
    [Abstract] [Full Text] [Related]

  • 8. [Diagnosis and therapy of Gaucher disease].
    Ehlen C, Heintges T, Niederau C.
    Med Klin (Munich); 1995 May 15; 90(5):284-90. PubMed ID: 7791695
    [Abstract] [Full Text] [Related]

  • 9. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 10. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM.
    Bull Acad Natl Med; 2002 Apr 20; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [Abstract] [Full Text] [Related]

  • 11. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM, Barnett NL, Kolodny EH.
    Clin Ther; 2005 Aug 20; 27(8):1215-27. PubMed ID: 16199246
    [Abstract] [Full Text] [Related]

  • 12. [Response criteria for enzyme substitution in Gaucher disease].
    Berthold F, Sieverts H, Benz-Bohm G, Landwehr P, Harzer K.
    Monatsschr Kinderheilkd; 1992 Oct 20; 140(10):740-4. PubMed ID: 1331780
    [Abstract] [Full Text] [Related]

  • 13. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?
    Brunel-Guitton C, Rivard GE, Galipeau J, Alos N, Miron MC, Therrien R, Mitchell G, Lapierre G, Lambert M.
    Mol Genet Metab; 2009 Feb 20; 96(2):73-6. PubMed ID: 19083253
    [Abstract] [Full Text] [Related]

  • 14. Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia.
    Benedik-Dolničar M, Kitanovski L.
    Pediatr Int; 2011 Dec 20; 53(6):1018-22. PubMed ID: 21883686
    [Abstract] [Full Text] [Related]

  • 15. Enzyme replacement in Gaucher disease.
    Beutler E.
    PLoS Med; 2004 Nov 20; 1(2):e21. PubMed ID: 15578103
    [Abstract] [Full Text] [Related]

  • 16. Gaucher disease with pulmonary involvement in a 6-year-old girl: report of resolution of radiographic abnormalities on increasing dose of imiglucerase.
    Lee SY, Mak AW, Huen KF, Lam ST, Chow CB.
    J Pediatr; 2001 Dec 20; 139(6):862-4. PubMed ID: 11743514
    [Abstract] [Full Text] [Related]

  • 17. The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy.
    Wilson C, Spearing R, Teague L, Robertson P, Blacklock H.
    Mol Genet Metab; 2007 Dec 20; 92(1-2):131-6. PubMed ID: 17604204
    [Abstract] [Full Text] [Related]

  • 18. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.
    Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S.
    Genet Med; 2009 Feb 20; 11(2):92-100. PubMed ID: 19265748
    [Abstract] [Full Text] [Related]

  • 19. Low-dose versus high-dose therapy for Gaucher disease: Goals and markers.
    Hollak CE, de Fost M, Aerts JM, vom Dahl S.
    Blood; 2007 Jan 01; 109(1):387; author reply 387-8. PubMed ID: 17190857
    [No Abstract] [Full Text] [Related]

  • 20. The cost of treating Gaucher disease.
    Beutler E.
    Nat Med; 1996 May 01; 2(5):523-4. PubMed ID: 8616707
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.